What is S. Boulardii?
S. boulardii (Saccharomyces boulardii) is a non-pathogenic yeast. It possesses probiotic activity that supports gastrointestinal health and immune function. This formula contains 500 mg (10 billion CFU) of S. boulardii per serving. This strain does not require refrigeration and has the ability to survive passage through the harsh gastric environment, withstanding high acidity, bile, and heat.
What are the benefits of S. Boulardii?
S. Boulardii may be beneficial for counterbalancing intestinal microorganisms disrupted by stress, poor nutrition, and toxins, strengthening the intestinal barrier, protecting the digestive mucosa from pathogens that may damage the intestinal lining, promoting healthy bowel function, and counterbalancing overgrowth of opportunistic bacteria and yeast.*
What is the recommended dose?
Two capsules per day is recommended.
When should I take it?
Doses should be separated between meals (e.g. can be taken at breakfast and dinner, or in the morning and evening), with or without food.
Can it be taken with thyroid medications?
S. Boulardii should be taken at least 30 to 60 minutes away from thyroid medications.
How long can I take S. Boulardii for?
S. Boulardii can be taken for 3 months to 2 years.
Can S. Boulardii cause constipation?
S. Boulardii has the potential to cause changes in bowel function, so it may be helpful to increase magnesium citrate intake while taking S. Boulardii.
Should S. Boulardii be discontinued if consuming it results in burping or discomfort in the stomach?
Burping and mild discomfort could be an indication that the beneficial yeast is working to maintain normal balance of intestinal flora. In this case, reducing the dose, alternating days, or taking it with food, may help ease discomfort in these situations. Please discontinue the supplement and consult with your practitioner if you experience moderate-severe or prolonged symptoms.
Can I take S. Boulardii if I am taking antibiotics?
Yes. S. Boulardii can help with counterbalancing the overgrowth of opportunistic bacteria and yeast, which may result from the use of antibiotics.*
Can I take S. Boulardii if I have SIBO or Candida?
S. Boulardii can help to counterbalance overgrowth of opportunistic bacteria and yeast, and we are unaware of any contraindications with SIBO and Candida, except in those who are immunocompromised and have reduced ability to fight infections. Please note, it is possible to experience an exacerbation of symptoms when starting S. Boulardii, or any probiotic, as the microbiome works to rebalance itself.*
The warning mentions those who are immunocompromised should not take S. Boulardii. Is S. Boulardii safe for use with Hashimoto’s?
S. Boulardii has been associated with fungemia (fungal infections that can spread through the bloodstream) or localized infections, in immunocompromised individuals. Those who are immunocompromised (such as those with AIDs and cancer) have a weakened immune system, and a reduced ability to fight infections and other diseases, or when taking certain medicines or treatments, such as anticancer drugs and radiation therapy.
However, Hashimoto's is typically associated with having an overactive immune system and not a lowered immune system. As such, having Hashimoto's does not necessarily mean a person is immunocompromised, but it is possible to both have Hashimoto’s and be immunocompromised. As always, please consult with your practitioner regarding your specific condition and medical needs, before taking S. Boulardii or any other supplement.
Do not use if you have an indwelling vascular catheter, or if you have a yeast allergy. Not to be used by those who are immunocompromised or those with risk factors for adverse events (e.g. patients with central venous catheters or increased bacterial translocation). Do not use if you are allergic or sensitive to any of the ingredients in this supplement.
Consult with a doctor before use if pregnant or breastfeeding.
Avoid if taking the following medications: blood thinners.
- Stier H, Bischoff SC. Saccharomyces boulardii CNCM I-745 influences the gut-associated immune system. MMW Fortschr Med. 2017;159 (Suppl 5):1-6. doi: 10.1007/s15006-017-9802-3.
- Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134(1):e176-91. doi: 10.1542/peds.2013-3950.
- Rodrigues AC, Cara DC, Fretez SH, Cunha FQ, Vieira EC, Nicoli JR, Vieira LQ. Saccharomyces boulardii stimulates sIgA production and the phagocytic system of gnotobiotic mice. J Appl Microbiol. 2000; 89(3):404-14.
- Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F, Marchiori B, Germain S, Bonier R, Hama A, Owens R, Lombardo D, Rigot V, Andre F. Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of Ecadherin recycling. J Crohns Colitis. 2017;11(8):999-1010. doi: 10.1093/ecco-jcc/jjx030.
- Terciolo C, Dapoigny M, Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019;12:67-82. doi: 10.2147/CEG.S181590.
- Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2015;42(7):793-801. doi: 10.1111/apt.13344.
- Dinleyici EC, Eren M, Dogan N, Reyhanioglu S, Yargic ZA, Vandenplas Y. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res. 2011;108(3):541-5. doi: 10.1007/s00436-010-2095-4.
- Szajewska H, Horvath A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Ailment Pharmacol Ther. 2015;41(12):1237-45. doi: 10.1111/apt.13214.
- Krasowska A, Murzyn A, Dyjankiewicz A, Lukaszewicz M, Dziadkowic D. The antagonistic effect of Saccharomyces boulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS Yeast Res. 2009;9(8):1312-21. doi: 10.1111/j.1567-1364.
- Akil I, Yilmaz O, Kurutepe S, Degerli K, Kavukcu S. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol. 2006 Jun;21(6):807-10.
- Kollaritsch H, Holst H, Grobara P, Wiedermann G. Prophylaxe der Reisediarrhöe mit Saccharomyces boulardii. Ergebnisse einer plazebokontrollierten Doppelblindstudie [Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr Med. 1993;111(9):152‐156.
- García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020;65(4):1134‐1143. doi:10.1007/s10620-019-05830-0.
- García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis. Dig Dis Sci. 2020;65(4):1134‐1143. doi:10.1007/s10620-019-05830-0
- El-Zawawy HT, Farag, HF, Tolba MM, Abdalsamea HA. Improving Hashimoto’s thyroiditis by eradicating Blastocystis hominis: Relation to IL-17. SAGE Journals. doi.org/10.1177/2042018820907013
- National Cancer Institute. Definition of immunocompromised. NIH. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunocompromised. Accessed August 17, 2020.